Skip to main content
Log in

Different clinical presentations of a lupus anticoagulant in the same family

  • Originals
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

A young man who had suffered several episodes of deep-vein thrombosis of the legs since the age of 20 had a myocardial infarction at the age of 33, at which time both a prolonged partial thromboplastin time (PTT), compatible with a lupus anticoagulant (LA), and decreased fibrinolytic capacity (FC) were found.

His sister presented with deep-vein thrombosis of a leg and subsequent pulmonary embolism when she was 18 years old. She had a miscarriage three years later and developed a hemolytic-uremic syndrome at the age of 35. The PT and FC were normal. Laboratory investigations of the parents revealed positive antinuclear antibodies in the mother's serum but no anomaly in the father.

This study suggests a familial tendency to develop autoimmune disorders associated with LA and thromboembolic complications related to decreased FC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

PTT:

Partial thromboplastin time

FC:

Fibrinolytic capacity

LA:

Lupus anticoagulant

TT:

Thrombin time

PT:

Prothrombin time

GPL:

Anticardiolipin antibodies IgG type

MPL:

Anticardiolipin antibodies IgM type

PC/FII:

Protein C/Factor II

PC/FX:

Protein C/Factor X

FII:

Factor II

FX:

Factor X

References

  1. Anonymous (1984) Lupus anticoagulant. Lancet 26:1157–1158

  2. Arnett FC, Schulmann LE (1976) Studies in familial systemic lupus erythematosus. Medicine 55:313–322

    PubMed  Google Scholar 

  3. Bloom EJ, Abrams DI, Rodgers G (1986) Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 256:491–493

    Article  PubMed  Google Scholar 

  4. Brown JH, Doherty CC, Allen DC, Morton P (1988) Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. Br Med J 296:1505

    Google Scholar 

  5. Byron MA, Cederholm-Williams SA (1987) Detection of antibodies to vascular endothelium: a possible contribution to thrombosis. Fibrinolysis 1:241–245

    Article  Google Scholar 

  6. Canoso RT, Sise HS (1982) Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol 13:121–129

    PubMed  Google Scholar 

  7. Colaco CB, Elkon KB (1985) The lupus anticoagulant. A disease marker in antinuclear antibody negative lupus that is cross-reactive with autoantibodies to double-stranded DNA. Arthritis Rheum 28:67–74

    PubMed  Google Scholar 

  8. Colman RW, Hirsh J, Marder VJ, Salzman EW (1987) In: Hemostasis and thrombosis. Basic principles and clinical practice, 2nd edn. Lippincott, Philadelphia, pp 832–840

    Google Scholar 

  9. Conley CL, Hartmann RC (1952) Hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 31:621–622

    Google Scholar 

  10. Elias M, Eldor A (1984) Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Arch Intern Med 144:510–515

    Article  PubMed  Google Scholar 

  11. Exner T, Barber S, Kronenberg H, Rickard KA (1980) Familial association of the lupus anticoagulant. Br J Haematol 45:89–96

    PubMed  Google Scholar 

  12. Farquharson RG, Pearson JF, John L (1984) Lupus anticoagulant and pregnancy management. Lancet 1:228–229

    Article  Google Scholar 

  13. Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJW (1985) Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol 19:265–275

    PubMed  Google Scholar 

  14. Grimaudo V, Hauert J, Bachmann F, Kruithof EKO (1988) Diurnal variation of the fibrinolytic system. Thromb Haemostas 59:495–499

    Google Scholar 

  15. Harris EN, Gharavi AE, Patel SP, Hughes GRV (1987) Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 68:215–222

    PubMed  Google Scholar 

  16. Laurell AB, Nilsson IM (1957) Hypergammaglobulinemia circulating anticoagulant and biologic false positive Wassermann reaction. J Lab Clin Med 49:694–707

    PubMed  Google Scholar 

  17. Lechner K, Pabinger-Fasching I (1985) Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 15:254–262

    PubMed  Google Scholar 

  18. Lechner K (1987) Lupus anticoagulants and thrombosis. In: Verstraete M, Vermylen J, Lijnen HR, Arnout J (eds) Thrombosis and haemostasis. Leuven University Press, pp 525–547

  19. Lubbe WF, Butler WS, Palmer SS, Liggins GC (1984) Lupus anticoagulant in pregnancy. Br J Obst Gynaecol 91:357–363

    Google Scholar 

  20. Stafford-Brady FJ, Gladman DD, Urowitz MB (1988) Successful pregnancy in systemic lupus erythematosus with an untreated lupus anticoagulant. Arch Intern Med 148:1647–1648

    Article  PubMed  Google Scholar 

  21. Tan EM, Cohen AS, Fries JF, Masi AT, Mac Shane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    PubMed  Google Scholar 

  22. Triplett DA, Brandt JT, Musgrave KA, Orr CA (1988) The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 259:550–554

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jolidon, R.M., Knecht, H., Humair, L. et al. Different clinical presentations of a lupus anticoagulant in the same family. Klin Wochenschr 69, 340–344 (1991). https://doi.org/10.1007/BF02115779

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02115779

Key words

Navigation